Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2004 2
2005 1
2010 2
2011 2
2013 3
2014 1
2015 3
2016 3
2017 6
2018 6
2019 4
2020 4
2021 5
2022 2
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab (Keytruda).
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Kwok G, et al. Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310. Epub 2016 Jul 11. Hum Vaccin Immunother. 2016. PMID: 27398650 Free PMC article. Review.
Based on these results, pembrolizumab was approved by the USA FDA for the treatment of advanced melanoma and NSCLC. Tumor cell PDL1 expression may be a valid response predictor. Molecular analysis also showed that tumors with high gene mutation burdens, which might result …
Based on these results, pembrolizumab was approved by the USA FDA for the treatment of advanced melanoma and NSCLC. Tumor cell PDL1 expressi …
Melanom.
Ugurel S, Gutzmer R. Ugurel S, et al. J Dtsch Dermatol Ges. 2023 Apr;21(4):343-347. doi: 10.1111/ddg.15053. Epub 2023 Mar 31. J Dtsch Dermatol Ges. 2023. PMID: 36999586 Review.
Known risk factors are UV radiation, light skin type, the presence of multiple atypical nevi, and a positive family history. Decisive for the course of the disease are a guideline-based diagnosis and therapy. ...
Known risk factors are UV radiation, light skin type, the presence of multiple atypical nevi, and a positive family history. Decisive for th …
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Noviello TMR, et al. Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4. Nat Commun. 2023. PMID: 37739939 Free PMC article. Clinical Trial.
Immunotherapy in melanoma: Recent advances and future directions.
Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Franklin C, et al. Eur J Surg Oncol. 2017 Mar;43(3):604-611. doi: 10.1016/j.ejso.2016.07.145. Epub 2016 Sep 2. Eur J Surg Oncol. 2017. PMID: 27769635 Review.
Despite all efforts of early diagnosis, metastatic melanoma still has a poor prognosis and remains a challenge for treating physicians. In recent years, improved knowledge of the pathophysiology and a better understanding of the role of the immune system in tumour control …
Despite all efforts of early diagnosis, metastatic melanoma still has a poor prognosis and remains a challenge for treating physician …
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D, Woodford R, Menzies AM, Zimmer L, Williamson A, Ramelyte E, Dimitriou F, Wicky A, Wallace R, Mallardo M, Cortellini A, Budillon A, Atkinson V, Sandhu S, Olivier M, Dummer R, Lorigan P, Schadendorf D, Long GV, Simeone E, Ascierto PA. Mallardo D, et al. J Transl Med. 2023 Oct 25;21(1):753. doi: 10.1186/s12967-023-04607-4. J Transl Med. 2023. PMID: 37880788 Free PMC article.
The patients whose glucose blood level increased after 3 months of treatment with nivolumab + relatinib compared to baseline (ratio of blood level at baseline/after 3 months > 1.5) had a worse prognosis than those whose glucose level had not increased. This result was o …
The patients whose glucose blood level increased after 3 months of treatment with nivolumab + relatinib compared to baseline (ratio of blood …
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
Millet A, Martin AR, Ronco C, Rocchi S, Benhida R. Millet A, et al. Med Res Rev. 2017 Jan;37(1):98-148. doi: 10.1002/med.21404. Epub 2016 Aug 29. Med Res Rev. 2017. PMID: 27569556 Review.
Melanoma is the deadliest form of skin cancer. While associated survival prognosis is good when diagnosed early, it dramatically drops when melanoma progresses into its metastatic form. ...
Melanoma is the deadliest form of skin cancer. While associated survival prognosis is good when diagnosed early, it dramatically drop …
Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M, Song F, Du X, Wang G, Yang Y, Chen K, Yang J. Hao M, et al. Cancer Lett. 2015 Apr 1;359(1):1-8. doi: 10.1016/j.canlet.2014.12.050. Epub 2015 Jan 8. Cancer Lett. 2015. PMID: 25578781 Review.
Melanoma is the most deadly cutaneous cancer primarily derived from melanocytes with a poor prognosis in advanced stage. The therapy regimen for early stage melanoma patients is surgical resection with adjuvant IFN-alpha-2b therapy. ...
Melanoma is the most deadly cutaneous cancer primarily derived from melanocytes with a poor prognosis in advanced stage. The therapy …
Engineering nanomedicines for improved melanoma therapy: progress and promises.
Bei D, Meng J, Youan BB. Bei D, et al. Nanomedicine (Lond). 2010 Nov;5(9):1385-99. doi: 10.2217/nnm.10.117. Nanomedicine (Lond). 2010. PMID: 21128721 Free PMC article. Review.
Moreover, in past decades, the overall survival for advanced unresectable melanoma exhibited a constancy of poor prognosis. Low response rates and serious adverse effects have been characteristic of standard therapy based on a combination of chemotherapeutic agents or immu …
Moreover, in past decades, the overall survival for advanced unresectable melanoma exhibited a constancy of poor prognosis. Low respo …
BRAF as a therapeutic target: a patent review (2006 - 2012).
Zambon A, Niculescu-Duvaz D, Niculescu-Duvaz I, Marais R, Springer CJ. Zambon A, et al. Expert Opin Ther Pat. 2013 Feb;23(2):155-64. doi: 10.1517/13543776.2013.741593. Epub 2013 Jan 7. Expert Opin Ther Pat. 2013. PMID: 23294221 Review.
46 results